Shots:
- ADEL has entered into an exclusive worldwide license agreement with Sanofi for the development & commercialization of ADEL-Y01 & related backup compounds
- As per the deal, ADEL will receive a non-refundable payment of $80M upfront plus development & commercial milestones, representing the total deal value of ~$1.04B, tiered royalties on net sales ranging up to double-digit percentages
- ADEL-Y01 is a humanized antibody targeting toxic acK280 tau, blocking its aggregation while sparing normal tau for the treatment of Alzheimer’s disease; discovered by ADEL & co-developed with Oscotec since 2020, it is in a global FDA-approved P-I trial
Ref: PR Newswire | Image: ADEL & Sanofi |Press Release
Related News: Regeneron and Sanofi Report the EC Approval of Dupixent (Dupilumab) for Chronic Spontaneous Urticaria (CSU)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
